Clinical Trial Update: A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial to evaluate the safety of Iftolvaptan in infants and children aged 28 days to under 18 years with autosomal recessive polycystic kidney d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Polycystic Kidney Disease

Drugs mentioned

• Iftolvaptan

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Recessive Polycystic Kidney (ARPKD) | Phase 3 | Status: RECRUITING